Match!

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Published on May 1, 2017in Gut17.94
· DOI :10.1136/gutjnl-2015-311079
Jean-Frederic Colombel129
Estimated H-index: 129
(ISMMS: Icahn School of Medicine at Mount Sinai),
Bruce E. Sands70
Estimated H-index: 70
(ISMMS: Icahn School of Medicine at Mount Sinai)
+ 11 AuthorsBrian G. Feagan95
Estimated H-index: 95
(UWO: University of Western Ontario)
Abstract
Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p Conclusions Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number NCT01177228, NCT00619489, NCT00783718, NCT00783692, NCT01224171, NCT00790933.
  • References (28)
  • Citations (220)
References28
Newest
#1Tim Wyant (Takeda Pharmaceutical Company)H-Index: 16
#2Jose Estevam (Takeda Pharmaceutical Company)H-Index: 2
Last.Maria Rosario (Takeda Pharmaceutical Company)H-Index: 12
view all 4 authors...
20 CitationsSource
#1Megan McAuliffe (Takeda Pharmaceutical Company)H-Index: 3
#2Stephan F. LanesH-Index: 16
Last.I. Fox (Takeda Pharmaceutical Company)H-Index: 15
view all 10 authors...
14 CitationsSource
#1Maria Rosario (Takeda Pharmaceutical Company)H-Index: 12
#2Nathanael L. DirksH-Index: 6
Last.I. Fox (Takeda Pharmaceutical Company)H-Index: 15
view all 10 authors...
93 CitationsSource
4 CitationsSource
#1Karly P. Garnock-Jones (Springer Science+Business Media)H-Index: 10
10 CitationsSource
#1Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 70
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
Last.Stephen B. Hanauer (U of C: University of Chicago)H-Index: 104
view all 14 authors...
322 CitationsSource
#1Mahmoud Mosli (UWO: University of Western Ontario)H-Index: 15
#2Jesus Rivera-Nieves (UC: University of California)H-Index: 1
Last.Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
view all 3 authors...
25 CitationsSource
#1Leon P. McLean (UMD: University of Maryland, College Park)H-Index: 9
#2Raymond K. Cross (UMB: University of Maryland, Baltimore)H-Index: 22
33 CitationsSource
#1Michael D. Kappelman (UNC: University of North Carolina at Chapel Hill)H-Index: 36
#2Dóra Körmendiné Farkas (Aarhus University Hospital)H-Index: 22
Last.John A. Baron (UNC: University of North Carolina at Chapel Hill)H-Index: 112
view all 7 authors...
84 CitationsSource
#1Maneesh Dave (Mayo Clinic)H-Index: 15
#2Treta Purohit (NYMC: New York Medical College)H-Index: 4
Last.Edward Vincent Loftus (Mayo Clinic)H-Index: 83
view all 4 authors...
61 CitationsSource
Cited By220
Newest
#1Jeffrey R. CurtisH-Index: 61
#2James D. LewisH-Index: 2
Source
#1David Faleck (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Adam Winters (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last.Ryan C. Ungaro (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 11
view all 34 authors...
3 CitationsSource
#1Saleh Al Draiweesh (UWO: University of Western Ontario)
#2Christopher Ma (U of C: University of Calgary)H-Index: 13
Last.Vipul Jairath (UWO: University of Western Ontario)H-Index: 14
view all 23 authors...
Source
#1Chrissy Bolton (John Radcliffe Hospital)
#2Kyriacos Mouyis (Barts Health NHS Trust)
Last.Alan Steuer (Wexham Park Hospital)H-Index: 4
view all 4 authors...
Source
Source
#1Simon Travis (John Radcliffe Hospital)H-Index: 64
Source
#1Robert Battat (UCSD: University of California, San Diego)H-Index: 11
#2Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
Last.Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
view all 4 authors...
Source
#1Christopher M. Johnson (Scott & White Hospital)H-Index: 2
#2Catherine D. Linzay (Baylor University Medical Center)
Last.Themistocles Dassopoulos (Scott & White Hospital)H-Index: 1
view all 3 authors...
Source
#1Silvio Danese (Humanitas University)H-Index: 63
#2WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
Last.Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
view all 10 authors...
1 CitationsSource
#1Bharati Kochar (UNC: University of North Carolina at Chapel Hill)H-Index: 6
#2Yue Jiang (UNC: University of North Carolina at Chapel Hill)
Last.Michael D. Kappelman (UNC: University of North Carolina at Chapel Hill)H-Index: 36
view all 7 authors...
Source
View next paperVedolizumab as induction and maintenance therapy for Crohn's disease